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DOI 10.1016/j.ccr.2011.05.007SUMMARYImatinib has revolutionized the treatment of BCR-ABL1+ chronicmyeloid leukemia (CML), but, inmost patients,
some leukemia cells persist despite continued therapy, while others become resistant. Here, we report that
PlGF levels are elevated in CML and that PlGF produced by bone marrow stromal cells (BMSCs) aggravates
disease severity. CML cells foster a soil for their own growth by inducing BMSCs to upregulate PlGF, which
not only stimulates BM angiogenesis, but also promotes CML proliferation and metabolism, in part indepen-
dently of BCR-ABL1 signaling. Anti-PlGF treatment prolongs survival of imatinib-sensitive and -resistant CML
mice and adds to the anti-CML activity of imatinib. These results maywarrant further investigation of the ther-
apeutic potential of PlGF inhibition for (imatinib-resistant) CML.INTRODUCTION
Chronic myeloid leukemia (CML) is caused by chromosomal
translocation t(9;22)(q34;q11) (‘‘Philadelphia chromosome’’)Significance
Imatinib has revolutionized the treatment of chronic myeloid leu
gence of resistance, and the limited efficacy in advanced dise
that PlGF, upregulated in bone marrow (BM) stromal cells by
proliferation and creates a ‘‘fertile soil’’ for CML. Treatment with
and in combination with imatinib. Anti-PlGF is also effective in a
these therapeutic avenues.
740 Cancer Cell 19, 740–753, June 14, 2011 ª2011 Elsevier Inc.that gives rise to the BCR-ABL1 fusion kinase (Druker, 2008;
Quintas-Cardama et al., 2009). This leukemogenic tyrosine
kinase (TK) promotes survival and proliferation of CML cells
(Van Etten, 2004). Because of its pivotal role in CMLkemia (CML). Yet, failure to eradicate the disease, the emer-
ase stages warrant alternative approaches. Here, we report
close contact with leukemia cells, increases leukemia cell
an anti-PlGF antibody prolongs survival of CMLmice, alone
n imatinib-resistant model, warranting further exploration of
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PlGF Blockade Prolongs Survival of CML Micepathogenesis, most therapies have focused on targeting BCR-
ABL1.
The BCR-ABL1 TK inhibitor (TKI) imatinib has revolutionized the
treatment of CML (Druker et al., 2006). Nonetheless, a subset of
patients fails imatinib therapy because of poor tolerance, loss of
response or resistance mostly due to acquired mutations in the
ABL1 TK domain (Quintas-Cardama et al., 2009). While imatinib
induces molecular remission in most patients, it generally fails
to completely eradicate the leukemic stem cell pool. Even
though some CML patients can arrest treatment without disease
recurrence, most relapse after treatment discontinuation (Mahon
et al., 2010) and responses are short-lived in end-stage disease
(Druker, 2008). Second-generation TKIs have been developed,
but some BCR-ABL1 mutations convey resistance to these drugs.
The T315I mutation is particularly problematic as it is one of the
common mechanisms of escape and resistance against second
generation TKIs (Druker, 2008).
Microenvironment-targeted treatment has gained increasing
attention in hemato-oncology. Targeting the bone marrow (BM)
environment may provide alternative opportunities to improve
the efficacy of anti-CML treatment for TKI-refractory or intolerant
cases (Konopleva et al., 2009; Lane et al., 2009). In line with find-
ings that CML is highly vascularized and angiogenesis contrib-
utes to leukemogenesis (Aguayo et al., 2000; Zetterberg et al.,
2004), vessel density is a predictor of CML progression and
patient survival (Korkolopoulou et al., 2003). However, the rele-
vance of angiogenesis in CML remains poorly characterized.
The angiogenic factor VEGF is upregulated by BCR-ABL1 in
CML cells while its levels and BM angiogenesis are reduced by
imatinib (Li et al., 2008). VEGF also promotes leukemic cell
growth and survival via autocrine effects. Nonetheless, mono-
therapy with inhibitors targeting VEGF or angiogenesis-related
factors has shown limited success in leukemia (Li et al., 2008;
Zahiragic et al., 2007), and clinical effects in CML have not
been reported yet.
Placental growth factor (PlGF) is a VEGF homolog that binds to
Flt1 (VEGFR1) and coreceptor neuropilin-1 (Npn1) (Fischer et al.,
2008). PlGF is a disease-specific cytokine, which is dispensable
in health but contributes tomalignant, inflammatory and ischemic
disorders (Carmeliet et al., 2001; Fischer et al., 2007, 2008; Vande
Veire et al., 2010). PlGF blockade with the anti-PlGF monoclonal
antibody (mAb) 5D11D4 inhibits solid tumor growth and angio-
genesis (Fischer et al., 2007; Van de Veire et al., 2010). PlGF is
a multitasking cytokine that not only affects endothelial, tumor,
inflammatory, and stromal cells, but also promotes survival of
hematopoietic precursors (Hattori et al., 2002). In vitro, PlGF stim-
ulates the growth of acute lymphoblastic leukemic (ALL) and
acute myeloid leukemia (AML) cells, while Flt1 is expressed by
human CML (Fragoso et al., 2006). However, the in vivo role of
PlGF in leukemia has not been validated. Prompted by the
suggestive link between PlGF and leukemia, we explored the
disease-candidate role of PlGF and the therapeutic potential of
pharmacological PlGF inhibition in CML models.
RESULTS
PlGF Is Upregulated in CML
To identify angiogenic targets inCML,weprofiled amousemodel
of CML-like myeloproliferative disease, induced by transplantingdonor BM cells, coexpressing the leukemogenic BCR-ABL1 onco-
protein and GFP (‘‘CML mice’’) (Daley et al., 1990). Healthy mice
ormice receivingmock-transducedBMwere used as ‘‘controls.’’
Among a selection of candidates, implicated in CML mouse
models or patients (Konopleva et al., 2009; Li et al., 2008), PlGF
and IL-6 were upregulated the highest in CML mice (Figures 1A
and 1B). As IL-6 has already been implicated in CML and PlGF
expression was upregulated the most, we focused on PlGF.
PlGF levels were low in the peripheral blood (PB) and BM
plasma in healthy and control mice, but increased in CML mice
(Figure 1C; see Figure S1A available online). Quantification of
GFP(+) BCR-ABL1(+) leukemia cells in the BM confirmed that
leukemia burden correlated with PB and BM plasma PlGF levels
(Figures 1D and 1E). sFlt1 was also elevated, but PlGF was upre-
gulated more, increasing the PlGF/sFlt1 molar ratio by 7.1 ± 1.6-
fold in the PB (Figure S1B) and by 2.7 ± 0.3-fold in the BMplasma
in end-stage CMLmice (N = 6–9; p < 0.05). PlGF levels were also
upregulated in CML patients. Compared to healthy human
subjects, plasma PlGF levels were elevated in CML patients in
chronic phase upon initial diagnosis and in blast crisis of treated
patients (Figure 1F). PlGF was also detectable in the BM plasma
of CML patients (62 ± 12 pg/ml; N = 7). The elevated PlGF levels
in murine and human CML prompted us to study its role further.
PlGF Is Produced by BM Stromal Cells
Cultured BCR-ABL1(+) cell lines of human (BV-173, K562) and
murine (32D; BaF/3) origin produced only negligible amounts of
PlGF (<9 pg/ml/48 hr/106 cells; N = 3). Leukemic CD34(+) cells
from CML patients and GFP(+) cells from CML mice also
produced minimal levels of PlGF mRNA (Figures 2A and 2B). In
contrast, high PlGF levels were produced by BM stromal cells
(BMSCs) from healthy mice (pg/ml/48 hr/106 cells: 4190 ± 204;
N = 3) and murine BMSC lines (pg/ml/48 hr/106 cells: 7280 ±
280 for OP9; 636 ± 11 for S17; N = 3). Similar results were ob-
tained when using BMSCs from CML patients (Figure 2A). Anal-
ysis of sorted BM cells from CML mice confirmed that PlGF was
predominantly expressed in GFP(–)CD45(–) stromal cells and
negligibly in non-malignant GFP(–)CD45(+) hematopoietic cells
or GFP(+) leukemia cells (Figure 2B). Notably, PlGF levels in
CD45(–) BM cells were higher in CML than healthymice, suggest-
ing that the presence of CML cells induced PlGF production in
BMSCs in vivo (Figure 2B).
We then analyzed which CD45(–) BMSC subtype produced
PlGF in CML mice. Analysis after FACS sorting showed that
only low amounts of PlGF were produced by CD45(–)CD133(+)
cells, enriched in nonhematopoietic progenitors, by
CD45(–)CD31(+) or CD45(–)VEGFR3(+) cells, enriched in endothe-
lial cells, or by CD45(–)CD31(-)CD44(+) cells (Figure 2C). Additional
sorting revealed that BM cells, immunonegative for CD45, CD31,
CD133 and CD44 produced the highest amounts of PlGF
(Figure 2C). These cells also expressed early osteogenic/fibro-
blastoid markers, such as collagen type I (Col1A1), Runx-2, alka-
line phosphatase (ALP), but not PPARg (adipogenic lineage) or
Sox9 (chondrogenic lineage) (Figure 2D).
PlGF Production by Stromal Cells Is Induced by
Leukemia Cells
Leukemia cells crosstalk with stromal cells and regulate each
other’s function (Ding et al., 2010a; Konopleva et al., 2009;Cancer Cell 19, 740–753, June 14, 2011 ª2011 Elsevier Inc. 741
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Figure 1. PlGF Levels in Different Stages
of CML
(A) RT-PCR analysis of mRNA transcript levels of
angiogenic genes in BM from CML mice, ex-
pressed as% change of the levels in BM of healthy
mice (N = 8; *p < 0.05). ND: not detectable.
(B) RT-PCR analysis of PlGF and IL-6 mRNA levels
in BM from healthy and leukemia mice (N = 8;
*p < 0.05).
(C) ELISA of plasma PlGF levels in healthy, control
mock, or leukemia mice (N = 3–9; *p < 0.05).
(D and E) Correlation of leukemia burden GFP(+)
BCR-ABL1(+) cell fraction) with PlGF protein levels in
PB plasma (N = 10; p < 0.01; r2 = 0.62) (D) or BM
plasma (N = 10; p < 0.01; r2 = 0.68) (E).
(F) ELISA of human PlGF plasma levels in healthy
individuals and in CML patients in chronic phase
and blast crisis (N = 9–32; *p < 0.05).
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PlGF Blockade Prolongs Survival of CML MiceNair et al., 2010). We therefore evaluated if such paracrine inter-
action regulated PlGF expression and cocultured human
leukemia cells on top of murine BMSCs. The use of this system
together with a specific ELISA for human or murine PlGF allowed
us to examine whether a tumor-stromal communication regu-
lated PlGF expression in the tumor (human) versus host
compartment (murine). When cultured alone, CML cells did not
produce detectable human PlGF, while BMSCs released murine
PlGF (see above). However, in coculture conditions, murine but
not human PlGF levels were increased above those in monocul-
tures, indicating that CML cells stimulated BMSCs to upregulate
PlGF expression, while the reverse paracrine communication did
not affect PlGF production in leukemia cells (Figure 3A). CML and
other leukemic cells upregulated PlGF production by BMSCs in
a dose-dependent manner (Figure 3B; Figure S2A). Similar742 Cancer Cell 19, 740–753, June 14, 2011 ª2011 Elsevier Inc.results were obtained with S17 stromal
cells, but not with osteoclasts or endothe-
lial cells (Figures S2B–S2D). Thus,
BMSCs upregulated PlGF when cocul-
tured with CML cells, while PlGF expres-
sion was undetectable in leukemia cells.
Role of NF-kB in Production of PlGF
To study how leukemia / stromal cell
interactions upregulated PlGF, we first
focused on CML cells. The PlGF-inducing
activity was not restricted to BCR-ABL1(+)
CML cells alone, since BCR-ABL1()
leukemia and other solid tumor cells (ex-
pressing distinct oncogenes) also induced
PlGF expression by BMSCs (Figures S2E
and S2F). Nonetheless, not every tumor
cell line upregulated PlGF in BMSCs and
some even suppressed PlGF production
(Figure S2G). Furthermore, inhibition or
silencing of BCR-ABL1 or some of its down-
stream signaling molecules (PI3K, RAS,
MEK) did not inhibit the ability of
BCR-ABL1(+) CML cells to upregulate PlGF
in BMSCs (Figures S2H–S2J).We then explored how CML cells induced PlGF expression in
BMSCs and focused on NF-kB, as this transcription factor upre-
gulates PlGF expression (Cramer et al., 2005). Overactivation of
NF-kB in BMSCs leads to a premalignant hematopoietic
disorder via a stromal/ leukemia crosstalk, but this pathway
has not been implicated in leukemia/ stromal cell interactions
yet. Compared to BMSC monocultures, BMSCs in coculture
with CML cells expressed higher levels of a NF-kB responsive
luciferase reporter (% of control: 177 ± 2%; N = 3; p < 0.005)
as well as of phosphorylated p65, a transcriptionally active NF-
kB subunit (Figure 3C). Moreover, BMSCs lacking IKKß, the
kinase that activates NF-kB signaling by phosphorylating the
NF-kB inhibitors Ik-Ba and Ik-Bß, failed to upregulate PlGF
when cocultured with CML cells (Figure 3D). In accordance,
treatment of BMSC monocultures with pharmacological NF-kB
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Figure 2. PlGF Production by Bone Marrow
Stromal Cells
(A) RT-PCR analysis of human PlGF mRNA levels
in CD34(+) cells of healthy donors, in CD34(+) cells
of CML patients in chronic phase or blast crisis,
and in BMSCs of CML patients (N = 3–7;
*p < 0.005).
(B) RT-PCR analysis of mouse PlGF mRNA levels in
GFP(+) leukemia cells, in GFP(–)CD45(+) hematopoi-
etic cells, and in nonhematopoietic GFP(–)CD45(–)
BMSCs from CML mice, and in CD45(+) or CD45(–)
cells from healthy mice (N = 3–4; *p < 0.05).
(C) RT-PCR analysis of mouse PlGF mRNA levels
in subfractions of GFP(–)CD45(–) BMSCs from CML
mice (N = 4, *p < 0.05).
(D) RT-PCR analysis of mRNA levels of Col1A1,
Runx-2, and alkaline phosphatase (ALP) in
CD45(–)CD44(–)CD31(–)CD133(–) BMSCs (N = 4).
ND, not detectable.
Cancer Cell
PlGF Blockade Prolongs Survival of CML Miceinhibitors lowered baseline PlGF production (indicating active
NF-kB signaling in baseline conditions) but, importantly, BMSCs
could no longer be stimulated by CML cells to upregulate PlGF
expression (Figure 3E). Also, immunostaining of sorted BM cells
revealed that phosphorylated p65 was detected in a larger
fraction of the PlGF-producing CD45(–)CD44(–) cells in CML
than control mice (% of control: 122% ± 6%; N = 5; p < 0.05).
The induction of PlGF release by BMSCs required contact with
CML cells, suggesting a possible role for integrins. We focused
on VCAM-1 and VLA-4 (a4b1 integrin) as NF-kB signaling is
enhanced by activation of VCAM-1 with VLA-4 (Zohlnhofer
et al., 2000), and expression of VLA-4 on leukemia cells and of
VCAM-1 on BMSCs plays a role in residual disease in AML and
resistance of ALL cells to chemotherapy (Matsunaga et al.,
2003). VLA-4 was expressed by CML cells (mRNA copies/105
copies b-actin: 440 ± 20; N = 5), while VCAM-1 was produced
by BMSCs (mRNA copies/105 copies b-actin: 45 ± 5; N = 5).
When supplementing a neutralizing anti-VLA-4 antibody (PS/2)
to the coculture, the upregulation of BMSC-derived PlGF by
leukemia cells was attenuated (Figure 3F). Similar findings
were obtained when using a VCAM-1/Fc, which traps VLA-4
(Figure 3F). Thus, via VLA-4/VCAM-1, leukemia/ BMSC inter-
actions induce PlGF production in BMSCs.
Loss or Inhibition of PlGF Prolongs Survival
of Leukemia Mice
To explore if PlGF is functionally important for CML, we trans-
planted BM cells, transduced with BCR-ABL1, from WT donors
in WT recipients (WT/WT) and transplanted BCR-ABL1(+)
PlGF/ BM cells in PlGF/ recipients (KO/KO). WT/WT
mice developed progressive GFP(+) leukocytosis and abundant
GFP(+) cells in the BM, which persisted until death (Figure 4A).
Affected mice succumbed to splenomegaly and pulmonary
hemorrhage, as reported (Daley et al., 1990). PlGF was
a disease-modifier, as CML onset occurred later in KO/KO
than WT/WT mice, and KO/KO mice survived longer (Fig-ure 4B). This phenotype was observed in a Balb/c and C57Bl/6
background, though the disease developed more slowly in the
C57Bl/6 background (Figure S3A).
We also explored if inhibition of PlGF phenocopied the loss of
PlGF and prolonged the survival of CML mice, using the anti-
PlGF mAb 5D11D4 (Van de Veire et al., 2010). WT/WT mice
were randomized and treatment with 5D11D4 or an isotype-
matched IgG control was initiated at 60 hr after transplantation,
when CML cells had engrafted the BM (see below). 5D11D4
prolonged the survival of CML mice (Figure 4C) and reduced
the leukemia burden, evidenced by lower white blood cell
(WBC) counts, spleen weight, GFP(+) leukemia cells in the BM
and higher hemoglobin (Hb) levels (Figures S3B–S3E).
At end stage, the BM in IgG-treated CMLmice was hypercellu-
lar,withdenselypacked leukemiacells andvessels,but fewadipo-
cytes and hematopoietic cells (Figure 4D). In contrast, when
analyzed on the same day, the BM of 5D11D4-treated mice con-
tained fewer leukemia cells, but more adipocytes and hematopoi-
etic cells, indicative of less advanced disease (Figure 4E). More-
over, when injecting BCR-ABL1(+) BaF3 cells, in which PlGF levels
in the BM were 2.2-fold higher than in healthy mice (N = 7/8; p <
0.01), 5D11D4 prolonged survival of these mice (Figure 4F). Over-
all, 5D11D4 delayed leukemia in different BCR-ABL1+ CML models
and phenocopied the slower disease upon PlGF deficiency.
Blockade of PlGF Does Not Alter Disease
Characteristics
PlGF blockade delayed onset and slowed down the course of
CML rather than changing the disease characteristics. Indeed,
analysis of the retroviral integration sites by Southern blotting
of genomic DNA from BM cells of CML mice showed the pres-
ence of one to three clonal integration sites per mouse and no
differences in the number of clones or proviral content between
genotypes or treatment conditions (Figure S3F). These results
suggest that the delay in disease onset and the less severe
disease upon PlGF-blockage were not due to disease alterationCancer Cell 19, 740–753, June 14, 2011 ª2011 Elsevier Inc. 743
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Figure 3. Effect of NF-kB Signaling on
Stromal Cell PlGF Expression
(A) ELISA measurement of murine and human
PlGF in the culture media of murine BMSCs
(mBMSCs), human CML (hCML) (BV-173) cells, or
coculture of both (N = 3; *p < 0.05). ND, not
detectable.
(B) ELISA measurement of murine PlGF in the
culture media of murine BMSCs cultured alone or
cocultured together with increasing numbers of
human CML (BV-173) cells (N = 3; *p < 0.05).
(C) Immunoblot of phosphorylated p65 (phospho-
p65) and total p65 levels in BMSC monocultures
and in BMSCs cocultured with CML (K562) cells;
quantification of phospho-p65/total p65 is shown
below each lane (mean ± SEM; N = 3, *p < 0.05).
(D) ELISA measurement of murine PlGF in the
culture media of murine IKKß+/+ or IKKß/
BMSCs, cultured alone or together with human
(BV-173) CML cells; effect of TNFa on BMSCs
monocultures is shown as control (N = 3,
*p < 0.05).
(E) ELISA measurement of PlGF in the culture
media of murine BMSCs, cultured alone or
together with human CML (K562) cells, in the
absence or presence of NF-kB pathway inhibition;
IKK-2 inhibitor IV (Ikk2-inh), or NF-kB activation
inhibitor II (Jsh23) (N = 3, *p < 0.05). NS: not
significant.
(F) ELISA measurement of PlGF in the culture
media of murine BMSCs, cultured alone or
together with human (BV-173) CML cells, in the
absence or presence of the VLA-4 inhibitor PS/2 or
the VLA-4 trap VCAM-1/Fc (N = 3, *p < 0.05).
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PlGF Blockade Prolongs Survival of CML Micewith loss of BCR-ABL1 vector integration or a difference in oligo-
clonal reconstitution. Furthermore, GFP(+) cells in the BM and
PB of all mice of each genotype (WT/WT; KO/KO mice) or
treatment condition (control IgG; 5D11D4) were uniformly
Gr1(+)Mac1(+) myeloid without shift to a B220(+) lymphoid pheno-
type (Table S1). Also, myeloperoxidase staining of granulocytes
did not reveal evidence for a phenotypic shift (Figure S3G). PlGF-
blockade did also not induce ectopic growth of solid tumors or
CD68(+) histiocytic sarcoma in the skull, brain, kidneys, or other
organs (observed in none of the IgG- and 5D11D4-treated
CML mice; N = 10; p = NS).
BlockadeofPlGFDoesNotAffectHomingorEngraftment
We next assessed if the prolonged survival upon PlGF blockage
was due to defective homing or engraftment of BCR-ABL1(+) BM
cells. To analyze homing, PKH26 dye-labeled BCR-ABL1(+) cells
were transplanted. FACS analysis at 16 hr after transplantation
revealed no difference in the fraction of GFP(+)PHK26(+) cells in
the BM of WT/WT and KO/KO mice (GFP(+)PHK26(+) cells,
% of BM cells in WT/WT mice: 100 ± 17 for WT/WT versus
96 ± 7 for KO/KO; N = 5; p = NS), suggesting unimpaired
homing. Noteworthy in this respect, in all survival experiments,
5D11D4 was administered from day 3 onward, i.e., after trans-
duced cells had homed to the BM.744 Cancer Cell 19, 740–753, June 14, 2011 ª2011 Elsevier Inc.To analyze if engraftment was altered in the absence of PlGF,
we transplanted BCR-ABL1(+) cells and counted GFP(+) cells in
the PB at weekly intervals. All WT/WT and KO/KO mice
maintained GFP(+) cells throughout the study and exhibited
a fully penetrant disease until death (Table S2), confirming sus-
tained short-term engraftment of BCR-ABL1(+) cells upon PlGF
blockage. Also, a comparable fraction of GFP(+)Lin(–)Sca1(+)
c-Kit(+)(LSK) cells was recovered in the BM of WT/WT and
KO/KO mice at 18 days post-transplantation (GFP+ LSK cells,
% of CML cells: 0.09 ± 0.02 for WT/WT versus 0.05 ± 0.02 for
KO/KO; N = 3; p = NS). Thus, the prolonged survival of
KO/KO mice is not explained by reduced engraftment of
leukemia-initiating cells, but rather due to a slowing of the
disease.
Loss of Host-Derived PlGF Slows Down CML Disease
To obtain further evidence that PlGF production by stromal
rather than leukemia cells regulated BCR-ABL1(+) leukemic
disease, additional cross-over studies were performed. Trans-
plantation of PlGF/ donor BCR-ABL1(+) BM cells did not prolong
survival ofWT recipients (KO/WT)while, conversely, transplan-
tation of WT donor BCR-ABL1(+) BM cells in PlGF/ recipients
(WT/KO) induced a survival advantage comparable to that
seen in KO/KO mice (Figure 4G).
AC D
E
G
F
B Figure 4. Effects of Loss or Inhibition of
PlGF on Survival of Leukemia Mice
(A) Analysis of white blood cell counts (WBC) in
PlGF/ mice receiving BCR-ABL1(+) BM from
PlGF/ donors (KO/KO) or in WTmice receiving
BCR-ABL1(+) BM from WT donors (WT/WT)
(N = 11; *p < 0.05).
(B) Kaplan-Meier survival analysis of KO/KO and
WT/WT mice (N = 11; *p < 0.05).
(C) Kaplan-Meier survival analysis of CML mice
treated with 5D11D4 or control IgG (N = 10–11;
*p < 0.02).
(D and E) H&E staining of BM in IgG-treated (D) or
5D11D4-treated CML mice (E) (bar: 150 mm).
(F) Kaplan-Meier survival analysis of mice with
BCR-ABL1(+) BaF3 leukemia treated with 5D11D4 or
IgG (N = 8/9; *p < 0.05).
(G) Kaplan-Meier survival analysis of WT/WT,
KO/WT, or WT/KOmice (N = 14–19; *p < 0.05).
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PlGF Blockade Prolongs Survival of CML MiceControl studies showed that only a negligible fraction of
donor-derived BMSCs ‘‘contaminated’’ the transplantation of
BCR-ABL1(+) BM cells. Indeed, after transplantation of BCR-
ABL1(+) BM cells from b-actin:GFP WT donors (expressing GFP
in BMSCs and other cells) in WT recipients, only very few GFP(+)
CD45(–) stromal cells were detected by FACS analysis of recip-
ient BM cells, even at preterminal stages (GFP(+)CD45(–) cells,
% of BM cells at day 18 and 28: 1.0% ± 0.6% and 2.1% ±
0.7%; N = 5). Similar results were obtained for PlGF/ recipients
(1.3% ± 0.6% and 1.0% ± 0.5%; N = 5). In addition, in WT and
PlGF/ recipients, 99.1% ± 0.2% and 99.7% ± 0.2% of
CD45(–)CD44(–) cells, the stromal population producing PlGF,
were GFP(–) and thus host derived. Moreover, in WT/KO
mice, only negligible PlGF protein levels were detected in the
BM plasma of recipient mice (3.1% ± 1.9% of the levels found
in WT/WT mice; N = 5), while PlGF was undetectable in the
PB (N = 5) (Figure S3H). Taken together, it is unlikely that theCancer Cell 19, 740–7negligible amount of PlGF, produced by
the very few cotransplanted donor
stromal cells contributed to the pheno-
type in a relevant manner. Indeed, if
a contamination of PlGF by donor-
derived WT stromal cells would be
relevant, the WT/KO and WT/WT
phenotype should phenocopy each
other, which was not the case. Moreover,
if the contribution of PlGF/ donor
stromal cells would be relevant, then
KO/WT mice should survive longer
than WT/WT mice, which was again
not the case.
To explore whether PlGF signaling in
cells of the BM milieu affected CML, we
used the genetic Flt1-TK/ mouse
model, which expresses a ‘‘knock-in’’
Flt1 variant lacking the cytosolic signaling
TK domains (Hiratsuka et al., 1998); Flt1-
TK/ mice were only available on
a C57Bl/6 background, in which CML
develops more slowly (see above). BCR-ABL1(+) BM cells of WT donors were transplanted into recipient
Flt1-TK/ mice (WT/TK) or control WT mice (WT/WT).
Notably, WT/TK mice developed less severe disease than
WT/WT mice: on day 59 after transplantation, 63% of WT/
WT mice (N = 19) but only 43% of WT/TK mice (N = 21) had
succumbed (p < 0.05 by Chi- square), while the median survival
was 41 days for WT/WTmice versus 75 days for WT/TKmice
(N = 19–21; p < 0.05). These results indicate that PlGF deter-
mined CML disease severity in part through Flt1 signaling in
the BM microenvironment.
5D11D4 Reduces Matrix Deposition and Osteolysis
Given that Flt1 signaling in BMstromal cells determined CML, we
studied how PlGF-blockage delayed CML by exploring various
stromal mechanisms. BM matrix accumulation is an adverse
prognostic factor in CML and associated with resistance to
imatinib (Buesche et al., 2007; Konopleva et al., 2009). Staining53, June 14, 2011 ª2011 Elsevier Inc. 745
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Figure 5. Effect of PlGF on BM matrix deposition in murine CML
(A) Morphometric analysis of reticulin-stained BM matrix accumulation in healthy mock mice, or in CML mice treated with control IgG or 5D11D4 (N = 5-7;
*p < 0.05).
(B–D) Representative examples of BM reticulin staining in healthy mock mice (B), and in IgG-treated (C) or 5D11D4-treated CML mice (D) (bar: 400 mm). Insets
show higher magnification (bar: 20 mm); arrows denote reticulin fibers.
(E) Analysis of PlGF/ BMSC cell accumulation in response to increasing concentration of PlGF in vitro (N = 3, *p < 0.05).
(F) Analysis of PlGF/ BMSC cell migration in the Boyden chamber assay with PlGF supplemented to the bottom or top chambers (N = 3, *p < 0.05).
(G) RT-PCR analysis of mRNA transcript levels of genes encoding matrix components in PlGF/BMSCs treated with PlGF, expressed as% change of the levels
in PlGF/ BMSCs treated with control vehicle (N = 3, for all: p < 0.05).
(H) Measurement of trabecular bone volume (BV), as a% of the total bone volume (TV) in healthy mockmice, and in CMLmice treated with control IgG or 5D11D4
(N = 5–7; *p < 0.05).
(I) Analysis of osteoclast numbers in the bone of CML mice treated with control IgG or 5D11D4 (N = 5, *p < 0.05).
Cancer Cell
PlGF Blockade Prolongs Survival of CML Micefor reticulin revealed an increase in reticulin deposition at
end-stage disease in IgG-treated CML mice as compared to
healthy mock mice, while 5D11D4 partially inhibited this
deposition (Figures 5A–5D). When staining for Sirius Red (SR)
to identify the deposition of reticulin, various types of collagen746 Cancer Cell 19, 740–753, June 14, 2011 ª2011 Elsevier Inc.and other matrix components, only few SR+ fibers were
detected in the healthy BM; in the BM of IgG-treated CML
mice, 3-fold more SR+ fibers were present, while 5D11D4
treatment partially prevented this increase in SR+ fiber deposi-
tion (Figures S4A–S4D).
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Figure 6. Effect of PlGF on BM Angiogen-
esis in Murine CML
(A) Microvessel density in CD31 stained bone
marrow from healthy mock mice, and from CML
mice treated with control IgG or 5D11D4 (N = 5–7;
*p < 0.05).
(B–D) Representative images of CD31+ bone
marrow sections (bar: 400 mm) from healthy mock
mice (B), IgG-treated CML mice (C), and 5D11D4-
treated CML mice (D). Insets show higher magni-
fication (bar: 150 mm).
(E) Analysis of the accumulation ofWT and PlGF/
ECs, cultured in conditions of serum starvation or
full medium (N = 5, *p < 0.05).
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PlGF Blockade Prolongs Survival of CML MiceWe also assessed whether PlGF affected BMSCs, as these
cells are known to produce matrix components in the BM
stroma. PlGF regulated the growth of these cells in an autocrine
manner, since PlGF deficiency reduced BMSC proliferation by
55% ± 4% (N = 6; p < 0.05), while PlGF dose-dependently
stimulated growth of PlGF/BMSCs (Figure 5E). PlGF also che-
moattracted PlGF/ BMSCs, since PlGF in the lower but not in
the upper Boyden chamber stimulated BMSC migration (Fig-
ure 5F). Similar mitogenic and chemotactic effects were
observed when treating WT BMSCs with PlGF (Figures S4E
and S4F). Treatment of PlGF/ BMSCs with PlGF also upregu-
lated the expression of genes, encoding matrix components in
the BM stroma, including collagen type III (Col3A1), the main
fiber type in reticulin, and, more modestly, collagen type I
(Col1A1), collagen type V (Col5A1), fibronectin (Fn1), and lami-
nin-a4 (Lama4) (Figure 5G). PlGF did, however, not alter the
production of the profibrotic factors PDGF-A, PDGF-B, PDGFRa
and PDGFRß, TGF-ß, or FGF2 (Figure S4G).
Osteolysis is a rare complication in CML. Compared to
untreated mock mice, CML mice treated with IgG showed signs
of trabecular bone loss at end-stage disease (Figure 5H; Figures
S4H–S4J). 5D11D4 treatment prevented this bone loss in CML
(Figure 5H; Figures S4H–S4J) and reduced the number of
osteoclasts (Figure 5I). These findings are in line with results
that PlGF affects Flt1-expressing osteoclasts (Coenegrachts
et al., 2010).Cancer Cell 19, 740–75D11D4 Inhibits Bone Marrow
Angiogenesis
We also studied BM vascularization in
CML mice at a time when IgG-treated
mice had end-stage disease. Morphom-
etry of CD31+ sections revealed an
increase in vessel density in IgG-treated
CML mice as compared with healthy
mice (Figures 6A–6C). 5D11D4 treatment
nearly completely blocked this angio-
genic burst (Figures 6A and 6D). To
assess whether PlGF affected angiogen-
esis directly, we tested the effect of
PlGF on ECs. Since primary mouse BM-
derived sinusoidal ECs (BMECs) could
not be obtained in sufficient numbers,
we isolated pulmonary ECs (pECs) and
observed lower proliferation of PlGF/than WT pECs, indicating that endogenous PlGF stimulated
ECs via an autocrine loop (Figure 6E). Similar differences were
seen for migration (% decrease versus control: 36% ± 5%;
N = 5; P < 0.05). These findings are consistent with reports
that PlGF induces various responses in cultured ECs (Landgren
et al., 1998; Van de Veire et al., 2010).
We also tested if PlGF activated BMECs in healthy mice in the
absence of leukemia cells and therefore intravenously injected
an adenovirus, encoding PlGF (AdPlGF) or a control adenovirus
(AdCtrl), as this gene transfer transduces hepatocytes, which
then release PlGF in the PB sufficient to stimulate angiogenesis
in peripheral organs (Van de Veire et al., 2010). Immunostaining
for CD31 after 7 days revealed that PlGF-gene transfer increased
the BMmicrovascular density by 36% ± 13% (N = 5; p = 0.02). In
accordance, counting of BrdU(+)CD45(–)CD31(+) ECs showed
that PlGF gene transfer stimulated BMEC proliferation by
32% ± 3% (N = 3; p < 0.05).
Bcr-Abl1-Independent Signaling of PlGF in CML Cells
We also explored if PlGF affected CML cells. Given that
BCR-ABL1+ cells express Flt1 and Npn1 (mRNA copies/105
copies b-actin: for Flt1, 7.2 ± 1.7 for BV-173 and 1.8 ± 0.4 for
K562; for Npn1: 7.4 ± 1.4 for BV-173 and 0.45 ± 0.04 for K562;
N = 5), we analyzed if PlGF modulated BCR-ABL1 activation.
Immunoblotting for a key phosphorylated tyrosine residue in
ABL1 (pY421-ABL1) showed that PlGF did not activate ABL1 in53, June 14, 2011 ª2011 Elsevier Inc. 747
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Figure 7. Analysis of Signaling Pathways
in CML cells
In each panel, the numbers below the immuno-
blots refer to the densitometric quantification of
the phosphorylated versus total protein levels, %
of baseline.
(A) Immunoblot of phosphorylated P-STAT5 and
total STAT5 levels in human CML (BV-173) cells,
treated with PlGF, imatinib (ima), or a combination
of both.
(B) Immunoblot of phosphorylated P-ERK and total
ERK levels in human CML (BV-173) cells, treated
with PlGF.
(C) Immunoblot of HIF-1a and SP1 (loading
control) levels in human CML (BV-173) cells,
treated with PlGF.
(D) Immunoblot of phosphorylated p-PLCg and
total PLCg levels in human CML (BV-173) cells,
treated with PlGF, imatinib, or a combination of
both.
Cancer Cell
PlGF Blockade Prolongs Survival of CML MiceCML cells (pY421-ABL1/total ABL1: 1.07 ± 0.02 after vehicle versus
0.97 ± 0.10 after PlGF; N = 3; p = NS).
Analysis of signaling targets downstream of BCR-ABL1 revealed
high baseline levels of phosphorylatedSTAT5 (P-STAT5) which PlGF
failed to further increase (Figure 7A). To exclude that the high
baseline activity of BCR-ABL1 masked an effect of PlGF, we
blocked BCR-ABL1 signaling by imatinib and then treated CML
cells with PlGF, but also in these conditions, PlGF was ineffective
in upregulating P-STAT5 levels (Figure 7A). Similar findings were
obtained for CRKL, PI3K, and p38MAPK (Figures S5A–S5C). These
findings are consistent with reports that PlGF does not regulate
STAT5 (Bartoli et al., 2000; Bellik et al., 2005) or variably affects
p38MAPK (Taylor et al., 2010). Phosphorylated AKT (P-AKT) levels
were low in baseline conditions and only insignificantly increased
byPlGF (P-AKT/totalAKT,%ofcontrol: 116%±39%;N=3;p=NS).
However, PlGF increased the phosphorylation of ERK1/2 (Fig-
ure 7B), a downstream target of both PlGF and BCR-ABL1 (Hazle-
hurst et al., 2009; Olsson et al., 2006). Another key pathway is the
hypoxia-inducible transcription factor HIF-1a, which is stabilized
in normoxic conditions by BCR-ABL1 in CML cells and by PlGF in
endothelial cells (Mayerhofer et al., 2002; Zhao et al., 2010).
Treatment of normoxic BCR-ABL1(+) cells with PlGF also
increased HIF-1a protein levels (Figure 7C), consistent with find-
ings that PlGF reduced by 38%± 12%mRNA levels of the prolyl-
hydroxylase PHD2 (a known negative regulator of HIFs); similar
changes in PHD2 expression cause biological effects (Mazzone
et al., 2009). In accordance, PlGF enhanced the transcriptional
HIF-activity in normoxic BCR-ABL1(+) cells, as measured by trans-
fecting CML cells with a HIF-inducible luciferase reporter (lucif-
erase activity, % of control: 139% ± 5%; N = 4; p < 0.05). PlGF
also elevated the levels of phosphorylated PLCg, another
common target of BCR-ABL1 and Flt1 (Arroyo et al., 2004), but
only after imatinib treatment, likely because its levels were too
high in baseline conditions (Figure 7D).748 Cancer Cell 19, 740–753, June 14, 2011 ª2011 Elsevier Inc.PlGF Stimulates CML Cell
Responses
We also assessed if PlGF regulated CML
responses in vitro. PlGF dose-depen-
dently stimulated proliferation of BCR-
ABL1+ cells, as evidenced by measuring 3H-Thymidine incorpo-
ration or counting CML cell numbers, an effect mediated via
Flt1 that was blocked by 5D11D4 (Figures 8A–8C; Figure S6A).
To document that PlGF also induced proliferation of CML cells
in vivo, we injected BrdU in CML mice at day 25 and sorted
BrdU+ leukemia cells from the BM of mice treated with IgG or
5D11D4. This analysis showed that 5D11D4 reduced the number
of BrdU+ leukemia cells by 38% ± 14% (N = 4; p = 0.06). PlGF
also increased CML cell migration by 37% ± 10% in a Boyden
chamber assay in vitro (N = 15; p < 0.05). Metabolic measure-
ments further indicated that PlGF stimulated the glycolytic flux
(Figure 8D), a known HIF-1a driven process that fuels malig-
nancy (Zhao et al., 2010). PlGF enhanced glycolysis despite
inhibition of BCR-ABL1 signaling (Figure 8D), showing that it can
affect CML cells independently of BCR-ABL1.
PlGF-Dependent Stromal/ Leukemia Crosstalk
Stromal/ leukemia interactions affectCMLproliferation, survival
and drug resistance (Nair et al., 2010). We therefore analyzed if
BMSC-derived PlGF regulated BCR-ABL1(+) CML growth. In
BMSC/CML cocultures, BMSCs are the only source of (murine)
PlGF, which can be selectively blocked by 5D11D4. In this assay,
5D11D4 inhibited CML cell proliferation to levels, observed when
thesecellswereculturedalone, indicating that themitogenic effect
was induced by paracrine PlGF release from BMSCs (Figure 8E).
Moreover, when coculturing CML cells with BMSCs, proliferation
of CML cells was stimulated more by WT than PlGF/ BMSCs
(Figure 8F). CML cells also stimulated BMSC proliferation by
inducing release of PlGF from BMSCs (Figures S6B and S6C).
5D11D4 Prolongs Survival of Imatinib-Treated
CML Mice
Given that PlGF affected both the BM stromal environment
and CML cells, and PlGF and BCR-ABL1 acted partially in
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Figure 8. Effects of PlGF on CML Cells
In Vitro and In Vivo
(A) 3H-Thymidine incorporation assay of human
CML (K562) cells treated with vehicle or PlGF
(N = 3; *p < 0.05).
(B) Measurement of the accumulation of BCR-
ABL1(+) leukemia cell lines of murine (BaF3) or
human origin (BV-173, K562) upon treatment with
control vehicle or PlGF (N = 3; *p < 0.05).
(C) Measurement of the accumulation of CML
(BV-173) cells in response to PlGF in the absence
or presence of an anti-Flt1 antibody or 5D11D4
(N = 3; *p < 0.05).
(D) Measurement of glycolytic flux in CML (K562)
cells in response to PlGF, in the absence or
presence of imatinib (N = 3; *p < 0.05 versus
control).
(E) Measurement of the accumulation of CML
(BV-173) cells, cultured alone or together with
BMSCs in the presence or absence of 5D11D4
(N = 3; *p < 0.05).
(F) Measurement of the accumulation of CML
(BV-173) cells, cultured alone or together with
PlGF+/+ or PlGF/ BMSCs (N = 3; *p < 0.05).
(G) Kaplan-Meier survival curve of CMLmice upon
monotherapy with 5D11D4 (N = 10; #p < 0.05
versus IgG) or imatinib (N = 10/16; #p < 0.05 versus
control; p = NS versus 5D11D4), or upon
combination therapy with 511D4 plus imatinib
(N = 10-18; *p < 0.05 versus imatinib alone and
5D11D4 alone); imatinib was administered once
a day.
(H) Kaplan-Meier survival curve of imatinib-resis-
tant CML mice, carrying the T315I BCR-ABL1
mutation, treated with control IgG or 5D11D4
(N = 12; *p < 0.05).
Cancer Cell
PlGF Blockade Prolongs Survival of CML Micea non-overlapping and complementary manner, we explored if
combination treatment of CML mice with 5D11D4 and imatinib
was superior to each monotherapy alone. Pilot experiments
showed that a dose of 100 mg/kg imatinib, given 13/day (qd)
or 23/day (bid) yielded similar results (Figure S6D). We therefore
treated CML mice with 5D11D4, imatinib or a combination of
both. Notably, monotherapy with imatinib or 5D11D4 prolonged
the survival of CMLmice, but the combination therapy prolonged
survival of leukemia mice significantly longer than each mono-
therapy alone, both when imatinib was given once or twice per
day (Figure 8G; Figure S6D).
5D11D4 Prolongs Survival in an Imatinib-Resistant CML
Mouse Model
These results also prompted us to investigate whether 5D11D4
could prolong the survival of mice developing an imatinib-resis-Cancer Cell 19, 740–7tant variant of CML. Therefore, a retro-
virus was used, expressing the imatinib-
resistant T315I variant of the BCR-ABL1
oncoprotein, found in CML patients who
fail to respond to imatinib and second
generation TKIs (Druker, 2008). This virus
was used to transduce BM cells (fromWT
donors) and generate a mouse model ofimatinib-resistant CML by transplanting these BCR-ABL1T315I
BM cells into WT recipients. Notably, treatment with 5D11D4
induced a survival advantage in this imatinib-resistant model
as well (Figure 8H).
DISCUSSION
This study provides evidence for a role for PlGF in CML. First,
PlGF levels in the BM plasma or PB correlate with BCR-ABL1(+)
leukemia load in CML mice and are elevated in CML patients.
Second, this cytokine stimulates BM angiogenesis and CML
cell growth. Third, PlGF gene deletion or inhibition by an anti-
PlGF antibody prolongs survival of CML mice. And fourth, the
beneficial effect of anti-PlGF treatment adds to the anti-CML
activity of imatinib in sensitive CML mice and prolongs the
survival of imatinib-resistant CML mice.53, June 14, 2011 ª2011 Elsevier Inc. 749
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PlGF Blockade Prolongs Survival of CML MiceWhile current anti-CML therapies have been largely ‘‘leukemia
cell-centered,’’ emerging evidence highlights the importance of
the BM stroma for the growth, survival and TKI resistance of
leukemia cells (Hazlehurst et al., 2009; Konopleva et al., 2009;
Lane et al., 2009; Nair et al., 2010). Leukemia cell 4 stromal
cell interactions are bidirectional, with forward signaling from
leukemia to stromal cells ensuring that the BM stroma becomes
a nurturing environment for the malignant cells, and reverse
signaling from stromal to leukemia cells promoting malignancy
and therapy resistance. Here, we show that PlGF is only mini-
mally produced by CML cells. However, leukemia cells instruct
BMSCs to produce increasing amounts of PlGF, a multitasking
cytokine that not only stimulates proliferation, migration, and
metabolism of CML cells, but also promotes angiogenesis in
the BM stroma. As such, PlGF drives a self-sustaining, reinforc-
ing vicious cycle, whereby CML cells induce the production of
PlGF by BMSCs, which results in increased leukemia load, that
in turn stimulates production of PlGF by the stroma, and so on.
Hence, by upregulating PlGF, leukemia cells create for them-
selves a fertile tumor-promoting ‘‘soil,’’ rich in vessel supply,
that fuels expansive growth. This mechanism can explain why
PlGF levels correlate with disease burden in CML mice. The
finding that PlGF is only upregulated by BMSCs when CML cells
are present in the BM clarifies why this cytokine is critical in path-
ologic leukemic conditions but not in normal hematopoiesis.
Precisely the fact that PlGF not only affects CML cells but also
the BM stromamay explain why PlGF-blockade not only adds to
the anti-CML activity of imatinib in the imatinib-sensitive model
but also prolongs survival in the imatinib-resistant model.
Several mechanisms contribute to the anti-CML effects of
PlGF-blockade. First, PlGF acts, at least partially, in parallel to
BCR-ABL1 in Flt1+ CML cells. Activation of CML cells by PlGF
did not increase tyrosine phosphorylation of BCR-ABL1 or its
downstream targets STAT5, CRKL, AKT, PI3K, or p38MAPK, but
activated PLCg, ERK1/2 and HIF-1a, targets shared by Flt1 and
BCR-ABL1. PlGF can thus act independently of BCR-ABL1 signaling
and induce pathways, that only partially overlap with those
induced by BCR-ABL1 (Bellik et al., 2005; Ding et al., 2010b; Ha-
zlehurst et al., 2009; Landgren et al., 1998; Quintas-Cardama
et al., 2009). Such molecular interactions could provide a mech-
anistic framework to explain why PlGF partially overcomes the
blockage of BCR-ABL1 by imatinib or acts in parallel of imatinib-
resistant T315I BCR-ABL1. Identifying leukemia cell-extrinsic
mechanisms that contribute to the resistance against
BCR-ABL1–specific TKIs is of great medical interest. So far, only
a few examples, other than PlGF, have been documented,
including GM-CSF, BMSC-medium, and Src-kinases (Donato
et al., 2003; Hazlehurst et al., 2009).
A second mechanism is that PlGF induced key changes in the
leukemic BMmicroenvironment, as evidenced by the prolonged
survival of CML mice with defective Flt1 signaling in cells of the
BM milieu. Infiltration of the BM with leukemia cells is known to
evoke an angiogenic response in hematological malignancies
including CML, and microvascular density is an independent
prognostic parameter for CML patients’ survival (Korkolopoulou
et al., 2003). Nonetheless, besides VEGF, angiopoietin-2 and
a few other molecules, the molecular basis of the angiogenic
switch in CML remains poorly defined (Li et al., 2008; Maffei
et al., 2009). PlGF is known to stimulate proliferation, migration750 Cancer Cell 19, 740–753, June 14, 2011 ª2011 Elsevier Inc.and survival of cultured ECs (Landgren et al., 1998; Van de Veire
et al., 2010). Moreover, PlGF stimulated BM angiogenesis in
healthy mice, indicating that leukemia cells were not absolutely
required for its angiogenic activity. Besides direct effects on
ECs, PlGF could also act as an ‘‘indirect angiogenic factor’’ via
effects on CML or stromal cells, for instance by stimulating the
release of additional angiogenic factors. Emerging evidence indi-
cates that the BMmilieu and themarrow vasculature are capable
of promoting the growth, survival and resistance of leukemic
cells by providing vital nutrients, cytokines and cell contact-
mediated signals (Konopleva et al., 2009; Lane et al., 2009).
PlGF-blockade partially blocked the deposition of reticulin-
and collagen-rich matrix in the BM of CML mice. In CML
patients, prominent BM fibrosis is a known adverse prognostic
factor and associated with resistance to imatinib (Buesche
et al., 2007; Konopleva et al., 2009). While a statistically signifi-
cant increase in matrix accumulation in the BM stroma of CML
mice was observed, it remains to be determined to what extent
the reduced BMmatrix deposition in PlGF-blockedmice is caus-
ally involved in reducing disease severity or only an indicator of
the less severe disease stage. Also, the overall relevance of
the relatively subtle matrix accumulation in CML mice for human
CML remains to be further defined. Moreover, PlGF-blockage
reduced osteolysis, a rare complication of CML, by inhibiting
osteoclast accumulation. We previously reported that PlGF
affects Flt1-expressing osteoclasts (Coenegrachts et al., 2010).
Bidirectional communication between leukemia and stromal
cells promotes CML, but only in a few cases have the respon-
sible signals produced by each class of cell types been identi-
fied. For instance, leukemia cell-released PDGF-B upregulates
VEGF in stromal cells (Ding et al., 2010a), while stromal cell-
produced factors (G-CSF, IL-3, or GM-CSF) mediate leukemia
cell resistance against TKIs (Nair et al., 2010). In this study, we
identified PlGF as a stromal cell-derived signal with activities
on both the malignant and host compartments, but also unveiled
that leukemia cells upregulate PlGF production in stromal cells
by activating NF-kB signaling. Over-activation of this pathway
in stromal cells leads to uncontrolled hematopoietic cell growth,
but NF-kB signaling has so far not been implicated in leukemia
/ stroma cell communication. Interestingly, binding of VLA-4
to VCAM-1 activates NF-kB (Zohlnhofer et al., 2000), while
NF-kB in turn upregulates VCAM-1 expression (Rajan et al.,
2008). This may not only explain why cell contact between
CML cells and BMSCs was required for the upregulation of
PlGF, but also suggests that this cell contact fuels a positive
feedback loop, whereby VCAM-1+ BMSCs reinforce binding of
VLA-4+ CML cells and ensure continued PlGF expression. Other
CML-derived signals that activate NF-kB signaling could be
involved as well. Interesting in this respect are recent findings
that cancer-associated fibroblasts (CAFs), a related population
of stromal cells in solid tumors, also exhibit a NF-kB gene signa-
ture (Erez et al., 2010; Quante et al., 2011). However, the precise
resemblance of the BMSC subpopulations, releasing PlGF,
producing matrix components or even stimulating angiogenesis
in CML on one end with the CAFs in solid tumors on the other
end, remains to be further elucidated. The ability of malignant
cells to induce PlGF in stromal cells is not restricted to CML
alone, but appears to be a more common paradigm, that other
BCR-ABL leukemogenic and BCR-ABL-independent tumors also
Cancer Cell
PlGF Blockade Prolongs Survival of CML Miceuse to hijack the stroma for their own benefit. Thus, while appli-
cable for CML per se, the present findings may have more
far-reaching implications for tumor biology in general than for
CML alone.
Finally, while these preclinical studies suggest other thera-
peutic opportunities, the translational applicability of PlGF-
blockade for CML will require further testing. Compared with
the overwhelming therapeutic benefit of imatinib, the therapeutic
potential of PlGF-blockade in this CML mouse model is obvi-
ously more modest. Nonetheless, our findings may prime further
interest in targeting the BM stroma or blocking BM angiogenesis
for improved treatment of CML in the future.EXPERIMENTAL PROCEDURES
More detailed methods are found in the Supplemental Experimental
Procedures.Animals
Wild-type Balb/C or C57BL/6 mice and PlGF/, Flt1-TK/ or IKKßl/l mice
were used. Adenoviral PlGF or control vector was administered intravenously.
Animal procedures were approved by the Institutional Animal Care and
Research Advisory Committee (KU Leuven); mouse experiments were per-
formed in accordance with the institutional and national guidelines and
regulations.Patient Samples
Patient samples from healthy controls, untreated patients upon primary diag-
nosis, and treated CML patients in blast crisis were collected in the university
hospitals of Leuven, Mannheim, Hamburg, Liverpool, and Glasgow and
analyzed for PlGF protein and BCR-ABL1 transcripts, in accordance with the
declaration of Helsinki and patients’ informed consent, and with the approval
of the ethical committee of the respective university hospitals.Cell Culture and In Vitro Functional Assays
Human and murine BCR-ABL1+ or BCR-ABL1- tumor cell lines (K562, BV-173,
Molm13, MV4-11, REH, BaF3, EOL-1, HL-60, PC3, MDA-MB-231, Nalm-6,
CRL-8024, CaKi-1, 32D), primary murine ECs, BMSCs or BMSC lines (S17,
OP9) were used in BMSC/tumor cell cocultures as detailed in Supplemental
Experimental Procedures. Proliferation, migration and luciferase reporter
assays are described in the Supplement. siRNA transfection was done by
electroporation.Elisa, Immunoblot , and RT-PCR
Human and murine PlGF, VEGF, Flt1, and sFlt1 were determined in cell culture
supernatants, blood plasma and BM by ELISA; immunoblotting of (phospho)
protein was with the antibodies listed in Supplemental Experimental Proce-
dures; RNA expression analysis was by Taqman qRT-PCR.Leukemia Models and Treatments
For the BaF3model, 13 106 BCR-ABL1+ BaF3 cells were injected i.v. into Balb/c
recipients. The CML transplantation model using GFP+ or GFP+BCR-ABL1+
BMSC was carried out as described (Daley et al., 1990; De Keersmaecker,
2008). Treatment with 5D11D4 (50 mg/kg; 33/wk) or an unrelated control anti-
body (1C8) and/or imatinib (100 mg/kg/once or twice per day) was started
2 days after transplantation. Survival of mice was monitored daily; BCR-ABL1
proviral integration was evaluated by Southern blot.Flow Cytometry and Sorting
BCR-ABL1(+) cells in peripheral blood and BM were analyzed as GFP+ cells by
flow cytometry. FACS or immunomagnetic bead sorting using specific marker
antibodies was as in Supplemental Experimental Procedures.BM Histology, Morphometry, and mCT Analysis
For BM stainings, paraffin sections from decalcified hind limb bones were
stained with hematoxylin, TRAP (osteoclasts), eosin (H&E), and Sirius Red
and immunostained for reticulin fibers, aSMA, collagen type I, and CD31.
Statistics
Data represent mean ± SEM of representative experiments, unless otherwise
stated. Statistical significance was calculated by Student’s t test or ANOVA.
For correlations, Pearson’s r coefficients were calculated, and survival of
mice was analyzed by log-rank tests.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and two tables and can be found with this article online at doi:10.
1016/j.ccr.2011.05.007.
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